Business Wire·Jun 29, 2026, 7:30 AM ET

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Tibulizumab is the first bispecific antibody targeting both BAFF & IL-17 currently in clinical development.
The Phase 2 TibuSHIELD trial in hidradenitis suppurativa (HS) completed enrollment with 247 participants, exceeding the target, with topline data expected in Q4 2026.
The Phase 2 TibuSURE trial in systemic sclerosis (SSc) exceeded its 80-participant target & is on track to complete enrollment in early July, with topline data expected in H1 2027.
Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by the end of 2026.
TibuSHIELD is a randomized, double-blind, placebo-controlled study evaluating tibulizumab in adults with moderate to severe HS, with a primary endpoint of percent change in total abscess & nodule count at Week 16.
TibuSURE is the first trial to evaluate dual IL-17 & BAFF inhibition in early diffuse cutaneous systemic sclerosis, with a primary endpoint of change in modified Rodnan Skin Score at Week 24.
Zura reported $225.6 million in cash & cash equivalents as of March 31, 2026, with funds expected to support operations through at least the end of 2028.
Additional pipeline candidates torudokimab & crebankitug have completed Phase 1/1b studies & are being evaluated across autoimmune conditions.